ATE492636T1 - Spezifisch in postmitotischen dopamin- produzierenden neuronalen vorläuferzellen exprimiertes gen - Google Patents

Spezifisch in postmitotischen dopamin- produzierenden neuronalen vorläuferzellen exprimiertes gen

Info

Publication number
ATE492636T1
ATE492636T1 AT03756723T AT03756723T ATE492636T1 AT E492636 T1 ATE492636 T1 AT E492636T1 AT 03756723 T AT03756723 T AT 03756723T AT 03756723 T AT03756723 T AT 03756723T AT E492636 T1 ATE492636 T1 AT E492636T1
Authority
AT
Austria
Prior art keywords
cells
pronector
postmitotic
dopamine
specifically expressed
Prior art date
Application number
AT03756723T
Other languages
English (en)
Inventor
Yasuko Nakagawa
Yuichi Ono
Yoshimasa Sakamoto
Eri Mizuhara
Tomoya Nakatani
Yoshimi Takai
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE492636T1 publication Critical patent/ATE492636T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03756723T 2002-10-22 2003-10-21 Spezifisch in postmitotischen dopamin- produzierenden neuronalen vorläuferzellen exprimiertes gen ATE492636T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002307573 2002-10-22
PCT/JP2003/013420 WO2004038018A1 (ja) 2002-10-22 2003-10-21 分裂停止後のドーパミン産生ニューロン前駆細胞に特異的に発現している遺伝子

Publications (1)

Publication Number Publication Date
ATE492636T1 true ATE492636T1 (de) 2011-01-15

Family

ID=32170942

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03756723T ATE492636T1 (de) 2002-10-22 2003-10-21 Spezifisch in postmitotischen dopamin- produzierenden neuronalen vorläuferzellen exprimiertes gen

Country Status (9)

Country Link
US (3) US7622270B2 (de)
EP (2) EP1795595A1 (de)
JP (1) JP4118877B2 (de)
CN (2) CN100572535C (de)
AT (1) ATE492636T1 (de)
AU (1) AU2003301576A1 (de)
DE (1) DE60335490D1 (de)
SG (1) SG146441A1 (de)
WO (1) WO2004038018A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE492636T1 (de) * 2002-10-22 2011-01-15 Eisai R&D Man Co Ltd Spezifisch in postmitotischen dopamin- produzierenden neuronalen vorläuferzellen exprimiertes gen
JP4573332B2 (ja) 2003-01-24 2010-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｌｒｐ４／Ｃｏｒｉｎドーパミン産生ニューロン増殖前駆細胞マーカー
DE602004021509D1 (de) * 2003-11-26 2009-07-23 Eisai R&D Man Co Ltd Spezifischer Marker Lmx1a für dopaminerge Neuronen
KR101375603B1 (ko) 2004-07-22 2014-04-01 에자이 알앤드디 매니지먼트 가부시키가이샤 Ｌｒｐ４／Ｃｏｒｉｎ 도파민 생산 뉴런 전구 세포 마커
JP4618736B2 (ja) * 2004-07-22 2011-01-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｌｒｐ４／Ｃｏｒｉｎドーパミン産生ニューロン前駆細胞マーカー
JP4717797B2 (ja) * 2004-07-22 2011-07-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｌｒｐ４／Ｃｏｒｉｎドーパミン産生ニューロン前駆細胞マーカー
CA2627593C (en) 2005-08-18 2012-04-24 Eisai R & D Management Co., Ltd. Dopaminergic neuron proliferative progenitor cell marker nato3
WO2007021004A1 (ja) * 2005-08-18 2007-02-22 Eisai R & D Management Co., Ltd. ドーパミン産生ニューロン増殖前駆細胞マーカーＭｓｘ１／２
WO2007119759A1 (ja) 2006-04-11 2007-10-25 Eisai R & D Management Co., Ltd. ドーパミン産生ニューロン前駆細胞マーカー１８７ａ５
CA2677996C (en) * 2007-02-09 2018-06-12 Eisai R&D Management Co., Ltd. Gaba neuron progenitor cell marker 65b13
CA2726426A1 (en) * 2008-06-04 2009-12-10 The Arizona Board Of Regents, On Behalf Of The University Of Arizona Diffuse large b-cell lymphoma markers and uses therefor
US20110201003A1 (en) * 2008-08-08 2011-08-18 Eisai R&D Management Co., Ltd. Method for obtaining purkinje progenitor cell by using neph3(65b13) and e-cadherin
EP2377921B1 (de) * 2008-12-22 2016-04-13 Eisai R&D Management Co., Ltd. Verfahren zur gewinnung von pankreasvorläuferzellen mittels neph3
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (de) 2010-10-01 2018-06-27 ModernaTX, Inc. Manipulierte nukleinsäuren und anwendungsverfahren dafür
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
JP6090937B2 (ja) * 2011-07-27 2017-03-08 国立大学法人京都大学 新規ドーパミン産生神経前駆細胞マーカー
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
CN112522425B (zh) * 2020-12-25 2023-11-28 武汉睿健医药科技有限公司 Dpc细胞鉴定分类用标记物基因、筛选方法及应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2089265C (en) 1990-08-30 2002-02-26 Lorin R. Debonte Seeds, plants and oils with altered fatty acid profiles
US5981165A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
WO1993002227A1 (en) 1991-07-15 1993-02-04 Eco-Tec Limited Process and apparatus for treating fluoride containing acid solutions
IT1251435B (it) 1991-09-04 1995-05-09 Sclavo Spa Vettore genetico per la integrazione multipla stabile di sequenze di dna nel genoma dei lieviti kluyveromyces lactis e saccharomyces cerevisiae e plasmidi che lo contengono.
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5285485A (en) 1993-02-01 1994-02-08 General Electric Company Composite nuclear fuel container and method for producing same
PT696205E (pt) * 1993-04-13 2002-07-31 Us Gov Health & Human Serv Utilizacao de linhas celulares fetais nauro-derivadas para terapia de transplantacao
US5753491A (en) 1993-04-13 1998-05-19 Us Health Use of neuro-derived fetal cell lines for transplantation therapy
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5554381A (en) 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
US6204053B1 (en) 1994-11-08 2001-03-20 Diacrin, Inc. Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6294383B1 (en) 1994-11-08 2001-09-25 The Mclean Hospital Corporation Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6277372B1 (en) 1994-11-08 2001-08-21 Diacrin, Inc. Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
KR100297899B1 (ko) 1995-03-13 2001-10-25 케네스 지. 프레스톤 세르톨리세포를이식함으로써정상소재의영양인자를생산하는방법및이러한세르톨리세포
US5830460A (en) 1995-03-13 1998-11-03 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
US6653134B2 (en) 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5753505A (en) 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030022293A1 (en) 1997-09-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE19756864C5 (de) 1997-12-19 2014-07-10 Oliver Brüstle Neurale Vorläuferzellen, Verfahren zu ihrer Herstellung und ihre Verwendung zur Therapie von neuralen Defekten
AU3888699A (en) 1998-05-07 1999-11-23 University Of South Florida Bone marrow cells as a source of neurons for brain and spinal cord repair
US6913925B1 (en) 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
US20030166132A1 (en) 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6610540B1 (en) 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
US7217565B2 (en) * 1999-02-12 2007-05-15 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
JP2001184757A (ja) 1999-12-27 2001-07-06 Aiwa Co Ltd テープレコーダ
WO2001068815A1 (en) 2000-03-14 2001-09-20 Es Cell International Pte Ltd Embryonic stem cells and neural progenitor cells derived therefrom
WO2001092482A1 (en) 2000-06-01 2001-12-06 Japan Science And Technology Corporation Method of concentrating and separating dopaminergic neurons
JP2002051775A (ja) 2000-06-01 2002-02-19 Japan Science & Technology Corp ドーパミン作動性ニューロンの濃縮・分離方法
CA2413986A1 (en) * 2000-06-22 2001-12-27 Biogen, Inc. Gp354 nucleic acids and polypeptides
EP1421179A1 (de) * 2001-08-24 2004-05-26 Nsgene A/S Isolierung von zellen aus neuralzellpopulationen unter verwendung von antikörpern gegen fa1/dlk1
ATE492636T1 (de) * 2002-10-22 2011-01-15 Eisai R&D Man Co Ltd Spezifisch in postmitotischen dopamin- produzierenden neuronalen vorläuferzellen exprimiertes gen
JP4573332B2 (ja) 2003-01-24 2010-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｌｒｐ４／Ｃｏｒｉｎドーパミン産生ニューロン増殖前駆細胞マーカー
DE602004021509D1 (de) 2003-11-26 2009-07-23 Eisai R&D Man Co Ltd Spezifischer Marker Lmx1a für dopaminerge Neuronen
CA2677996C (en) * 2007-02-09 2018-06-12 Eisai R&D Management Co., Ltd. Gaba neuron progenitor cell marker 65b13

Also Published As

Publication number Publication date
SG146441A1 (en) 2008-10-30
CN1891826A (zh) 2007-01-10
EP1561814A4 (de) 2005-12-07
WO2004038018A1 (ja) 2004-05-06
US20070122882A1 (en) 2007-05-31
CN1891826B (zh) 2011-09-14
US7622270B2 (en) 2009-11-24
CN1729290A (zh) 2006-02-01
EP1561814B1 (de) 2010-12-22
JPWO2004038018A1 (ja) 2006-02-23
EP1795595A1 (de) 2007-06-13
DE60335490D1 (de) 2011-02-03
AU2003301576A1 (en) 2004-05-13
US8039224B2 (en) 2011-10-18
JP4118877B2 (ja) 2008-07-16
EP1561814A1 (de) 2005-08-10
US20060239978A1 (en) 2006-10-26
CN100572535C (zh) 2009-12-23
US20100203570A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
ATE492636T1 (de) Spezifisch in postmitotischen dopamin- produzierenden neuronalen vorläuferzellen exprimiertes gen
Doucet-Beaupré et al. Cell fate determination, neuronal maintenance and disease state: The emerging role of transcription factors Lmx1a and Lmx1b
HRP20100187A2 (hr) Uporaba eritropoetina
DE602004030464D1 (de) Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
MX2012005450A (es) Constructo de vector virico novedoso para sintesis dopa continua optimizada especificamente de neuronas in vivo.
MXPA05012645A (es) Piridopirazinas novedosas y su uso como moduladores de cinasa.
ECSP066355A (es) Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2
DE602006018768D1 (de) Konditionell immortalisierte adulte langzeit-stammzellen und verfahren zur herstellung und verwendung von solchen zellen
DE60335028D1 (de) Quinazolinone als kaliumkanalmodulatoren
GT200200039A (es) Uso de agonistas inversos de gaba a en combinacion con agonistas parciales del receptor de nicotina, estrogenos,moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos
MX2009005496A (es) Uso de una composicion que contiene una celula madre mesenquimal derivada de sangre del cordon umbilical humano para inducir diferenciacion y proliferacion de celulas precursoras neurales o celulas madre neurales a celulas neurales.
FR2889526B1 (fr) 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
NZ596244A (en) Treatment of neurodegenerative diseases
WO2005021704A3 (en) In vitro generation of gabaergic neurons from embryonic stem cells and their use in the treatment of neurological disorders
MY159562A (en) Adipose tissue derived stromal cells for the treatment of neurological disorders
MXPA05012592A (es) Nuevas piridopirazinas y uso de las mismas como inhibidores de cinasa.
WO2007022437A3 (en) Therapeutic agents for the treatment of cancer and metabolic disorders
EP1712638A4 (de) Für dopamin produzierendes neuron spezifischer marker lmx1a
WO2006008028A8 (de) Neue 6-formyl-tetrahydropteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel, u.a. gegen krebs
AR033141A1 (es) Produccion de neuronas tirosina hidroxilasa positivas
CR9395A (es) Compuestos utiles para inhibir chk1
UY28733A1 (es) Compuestos quimicos
EP1535934A4 (de) Hydriertes copolymer, verfahren zu seiner herstellung und dieses enthaltende hotmelt-klebstoffzusammensetzung
DE602004021138D1 (de)
DE602005010047D1 (de) Nervenwachstumsfaktor sezernierende menschliche therapeutische zellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties